depatuxizumab mafodotin

Home
Ligands
depatuxizumab mafodotin

GtoPdb Ligand ID: 7970

Synonyms: ABT-414

Comment: Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate (ADC), which targets a unique tumour-specific EGFR epitope in some cancer cells [5]. The antibody portion recognises EGFR in glioblastoma cells with EGFR gene amplification or expressing the truncated Δ2-7 EGFR mutant (aka EGFRvIII) [2-3]. The antibody is linked to the cytotoxic agent, monomethyl auristatin F (MMAF; PubChem CID 56841603) (information derived from Phillips et al. (2013) [4] and Abbvie's webpage for oncology pipeline compounds and references therein [1].

References
1. abbvie. Oncology Pipeline [FOR HEALTHCARE PROFESSIONALS]. Accessed on 21/11/2014. Modified on 21/11/2014. abbvie.com, http://www.abbvie.com/oncology/home/pipeline.html
2. Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC et al.. (2002) Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer, 98 (3): 398-408. [PMID:11920591]
3. Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM. (2001) Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res, 61 (14): 5355-61. [PMID:11454674]
4. Phillips AC, Boghaert ER, Vaidya KS, Ansell PJ, Shalinsky DR, Zhang Y, Voorbach MJ, Mudd S, Holen KD, Humerickhouse RA et al.. (2013) ABT-414: An anti-EGFR antibody-drug conjugate as a potential therapeutic for the treatment of patients with squamous cell tumors [Abstract]. MMol Cancer Ther, 12 (11 Supplement): A250.
5. Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, DeVries PJ, Cheng D, Meulbroek JA, Buchanan FG et al.. (2016) ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Mol Cancer Ther, 15 (4): 661-9. [PMID:26846818]

References

1. abbvie.
Oncology Pipeline [FOR HEALTHCARE PROFESSIONALS].
Accessed on 21/11/2014. Modified on 21/11/2014. abbvie.com, http://www.abbvie.com/oncology/home/pipeline.html

2. Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC et al.. (2002)
Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
Int J Cancer, 98 (3): 398-408. [PMID:11920591]

3. Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM. (2001)
Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Cancer Res, 61 (14): 5355-61. [PMID:11454674]

4. Phillips AC, Boghaert ER, Vaidya KS, Ansell PJ, Shalinsky DR, Zhang Y, Voorbach MJ, Mudd S, Holen KD, Humerickhouse RA et al.. (2013)
ABT-414: An anti-EGFR antibody-drug conjugate as a potential therapeutic for the treatment of patients with squamous cell tumors [Abstract].
MMol Cancer Ther, 12 (11 Supplement): A250.

5. Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, DeVries PJ, Cheng D, Meulbroek JA, Buchanan FG et al.. (2016)
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.
Mol Cancer Ther, 15 (4): 661-9. [PMID:26846818]